Company news

BioVie Inc. news in 2023

BioVie Inc.'s news releases, calls and decks from 2023, newest first.

View company

BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

November 28, 2023

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

November 12, 2023

BioVie to Participate in the Truist Securities BioPharma Symposium

November 1, 2023

BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8: 00 AM ET

October 29, 2023

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023

October 25, 2023

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients

October 24, 2023

BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD

October 18, 2023

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

September 25, 2023

BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation

September 19, 2023

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

September 18, 2023

BioVie chief social impact officer sees major need for Alzheimer’s support and research

September 11, 2023

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

September 10, 2023

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023

September 6, 2023

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

August 30, 2023

BioVie Set to Join the Russell 2000® and Russell 3000® Indexes

June 22, 2023

BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

April 16, 2023

BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023

March 20, 2023

BioVie Announces Registration Details for "BioVie Day" Webinar

March 13, 2023

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

March 12, 2023

BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo

March 5, 2023

BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease

March 1, 2023

BioVie Announces “BioVie Day” to be held March 23, 2023

February 20, 2023

Decks in 2023